These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Hoshino K; Muro Y; Sugiura K; Tomita Y; Nakashima R; Mimori T Rheumatology (Oxford); 2010 Sep; 49(9):1726-33. PubMed ID: 20501546 [TBL] [Abstract][Full Text] [Related]
8. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis]. Gan YZ; Li YH; Zhang LH; Ma L; He WW; Jin YB; An Y; Li ZG; Ye H Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1001-1008. PubMed ID: 33331305 [TBL] [Abstract][Full Text] [Related]
9. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies. Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950 [TBL] [Abstract][Full Text] [Related]
10. Inflammatory Myopathies with Cutaneous Involvement: from Diagnosis to Therapy. Dourmishev LA Folia Med (Plovdiv); 2017 Mar; 59(1):7-13. PubMed ID: 28384112 [TBL] [Abstract][Full Text] [Related]
11. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets. Merlo G; Clapasson A; Cozzani E; Sanna L; Pesce G; Bagnasco M; Burlando M; Parodi A Arch Dermatol Res; 2017 Mar; 309(2):87-95. PubMed ID: 27928683 [TBL] [Abstract][Full Text] [Related]
12. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis. Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537 [TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical features between patients with anti-synthetase syndrome and dermatomyositis: results from the MYONET registry. Hum RM; Lilleker JB; Lamb JA; Oldroyd AGS; Wang G; Wedderburn LR; Diederichsen LP; Schmidt J; Danieli MG; Oakley P; Griger Z; Nguyen Thi Phuong T; Kodishala C; Vazquez-Del Mercado M; Andersson H; De Paepe B; De Bleecker JL; Maurer B; McCann L; Pipitone N; McHugh N; New RP; Ollier WE; Krogh NS; Vencovsky J; Lundberg IE; Chinoy H; Rheumatology (Oxford); 2024 Aug; 63(8):2093-2100. PubMed ID: 37698987 [TBL] [Abstract][Full Text] [Related]
14. [Dermatomyositis: new antibody, new classification]. Bolko L; Gitiaux C; Allenbach Y Med Sci (Paris); 2019 Nov; 35 Hors série n° 2():18-23. PubMed ID: 31859626 [TBL] [Abstract][Full Text] [Related]
15. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. Betteridge Z; Tansley S; Shaddick G; Chinoy H; Cooper RG; New RP; Lilleker JB; Vencovsky J; Chazarain L; Danko K; Nagy-Vincze M; Bodoki L; Dastmalchi M; Ekholm L; Lundberg IE; McHugh N; J Autoimmun; 2019 Jul; 101():48-55. PubMed ID: 30992170 [TBL] [Abstract][Full Text] [Related]
16. Autoantibodies in polymyositis and dermatomyositis. Ghirardello A; Bassi N; Palma L; Borella E; Domeneghetti M; Punzi L; Doria A Curr Rheumatol Rep; 2013 Jun; 15(6):335. PubMed ID: 23591825 [TBL] [Abstract][Full Text] [Related]
17. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan. Iwata N; Nakaseko H; Kohagura T; Yasuoka R; Abe N; Kawabe S; Sugiura S; Muro Y Mod Rheumatol; 2019 Sep; 29(5):802-807. PubMed ID: 30092736 [No Abstract] [Full Text] [Related]
18. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease. Li L; Wang H; Wang Q; Wu C; Liu C; Zhang Y; Cheng L; Zeng X; Zhang F; Li Y J Neurol Sci; 2019 Feb; 397():123-128. PubMed ID: 30616054 [TBL] [Abstract][Full Text] [Related]